Home About Us Physicians

Oncology Imaging

Positron emission tomography (PET) and computerized tomography (CT) are both state-of-the-art imaging tools that your doctor has recommended to provide information that is important to your diagnosis and will help you and your physician make more informed decisions about your treatment path. The PET/CT scan utilizes a glucose based radiopharmaceutical called Fludeoxyglucose F 18 Injection (FDG). PET/CT scans demonstrate how organs and tissues are functioning by showing how much FDG is taken up by the cells.

Important Safety Information
FLUDEOXYGLUCOSE F 18 INJECTION, USP
For Intravenous Use

Important Safety Information

Radiation Risk: Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

Blood Glucose Levels: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to administration.

View full important safety information for Fludeoxyglucose F 18 Injection

Patient Preparation Instructions

Carefully follow these preparation instructions.
more

What to Expect

Read this useful information to help you prepare for your appointment.
more

Understand more about medical radiation
more

Following the Scan

Understand the next steps following your PET/CT scan.
more

Safety Information

Read important safety information
more
Indications and Important Safety Information

FLUDEOXYGLUCOSE F 18 INJECTION, USP

For Intravenous Use

INDICATIONS AND USAGE
Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:

Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

IMPORTANT SAFETY INFORMATION
Radiation Risk:
Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

Blood Glucose Levels: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to administration.

ADVERSE REACTIONS
Hypersensitivity reactions with pruritis, edema and rash have occurred; have emergency resuscitation equipment and personnel immediately available.

Click here to view the full prescribing information for Fludeoxyglucose F 18 Injection

PETNET Solutions, 810 Innovation Drive, Knoxville, Tennessee, USA